5-[1-(Tetrahydro-2H-pyran-4-yl)[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]pyridine-3-sulfonamide

ID: ALA4863567

PubChem CID: 164624014

Max Phase: Preclinical

Molecular Formula: C19H18N6O3S

Molecular Weight: 410.46

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  NS(=O)(=O)c1cncc(-c2ccc3ncc4nnc(C5CCOCC5)n4c3c2)c1

Standard InChI:  InChI=1S/C19H18N6O3S/c20-29(26,27)15-7-14(9-21-10-15)13-1-2-16-17(8-13)25-18(11-22-16)23-24-19(25)12-3-5-28-6-4-12/h1-2,7-12H,3-6H2,(H2,20,26,27)

Standard InChI Key:  HYSFHTXNKQSESE-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 29 33  0  0  0  0  0  0  0  0999 V2000
   33.4760  -16.6451    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   33.0715  -17.3550    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   33.8885  -17.3503    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   34.4940  -19.8189    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.4928  -20.6426    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.2050  -21.0557    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.2032  -19.4101    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.9159  -19.8153    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.9167  -20.6385    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.6294  -21.0496    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   37.3418  -20.6347    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.6238  -19.4051    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   37.3360  -19.8055    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.9357  -19.2518    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   37.5982  -18.5115    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   36.7859  -18.6038    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.2295  -18.0003    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.4814  -17.2164    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.9290  -16.6112    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.1258  -16.7842    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   34.8780  -17.5680    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.4293  -18.1789    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.7841  -19.4107    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.7852  -18.5882    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.0741  -18.1758    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.3656  -18.5887    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.3684  -19.4142    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   33.0759  -19.8189    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.3652  -16.9507    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  2  0
  4  5  2  0
  5  6  1  0
  6  9  2  0
  8  7  2  0
  7  4  1  0
  8  9  1  0
  9 10  1  0
 10 11  2  0
 11 13  1  0
 12  8  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 12  1  0
 17 18  1  0
 17 22  1  0
 18 19  1  0
 19 20  1  0
 20 21  1  0
 21 22  1  0
 16 17  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 23  1  0
  4 23  1  0
 25  2  1  0
  2 29  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4863567

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 410.46

Molecular Weight (Monoisotopic): 410.1161

AlogP: 1.88

#Rotatable Bonds: 3

Polar Surface Area: 125.36

Molecular Species: NEUTRAL

HBA: 8

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 9.45

CX Basic pKa: 2.02

CX LogP: -0.43

CX LogD: -0.44

Aromatic Rings: 4

Heavy Atoms: 29

QED Weighted: 0.55

Np Likeness Score: -1.51

References

1. Berger M, Wortmann L, Buchgraber P, Lücking U, Zitzmann-Kolbe S, Wengner AM, Bader B, Bömer U, Briem H, Eis K, Rehwinkel H, Bartels F, Moosmayer D, Eberspächer U, Lienau P, Hammer S, Schatz CA, Wang Q, Wang Q, Mumberg D, Nising CF, Siemeister G..  (2021)  BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies.,  64  (17.0): [PMID:34428039] [10.1021/acs.jmedchem.1c00762]

Source

Source(1):

• Scientific Literature